ClinicalTrials.gg

Program

JMKX003142

A development code. Also written as “JMKX003142 tablets”, “JMKX003142 Injection” and “JMKX003142 will be administered orally”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Edema · Heart Failure, led by Jemincare.

Furthest: phase 3, since Sep 7, 202611 company-led studies, 9 open or runningNext primary completion: Feb 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare119 open or runningphase 3since Sep 7, 2026Oct 6, 2023Feb 28, 2027phase 2 · NCT06800651

Also a collaborator on its studies: zhejiang-hangyu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2023First study: phase 1 study in Safety and TolerabilityFirst studyNCT06079541 · 106 planned · China
  2. Mar 18, 2024Phase 1 study in Healthy AdultNCT06344533 · 78 planned · China
  3. Oct 23, 2024Phase 1 study in Polycystic Kidney, Autosomal DominantNCT06658964 · 48 planned
  4. Oct 31, 2024Phase 2 study in Edema SecondaryNCT06670534 · 133 enrolled · China
  5. Jan 20, 2025Phase 2 study in Polycystic Kidney, Autosomal DominantNCT06800651 · 135 planned · China
  6. Apr 22, 2025Phase 2 study in Edema, CardiacNCT06949020 · 160 enrolled · China
  7. Mar 2, 20262 phase 1 studies in Polycystic Kidney, Autosomal DominantNCT07463053, NCT07470177
  8. Apr 27, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07565441 · 112 planned
  9. Sep 7, 2026Phase 3 study in EdemaPhase 3 reachedNCT07841093 · 240 planned · China
  10. Oct 26, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07909070 · 32 planned

Ahead

  1. Nov 15, 2026Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07565441
  2. Feb 28, 2027Primary completion: phase 2 study in Polycystic Kidney, Autosomal DominantNCT06800651
  3. May 30, 2027Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07909070
  4. Apr 30, 2028Primary completion: phase 3 study in EdemaNCT07841093

TargetBeta

AVP →read by rule
“JMKX003142 is an arginine vasopressin(AVP)-V2R antagonist which shows a remarkable diuretic effect in healthy volunteers(phase 1 study) and renal edema patients(phase 2 study).In this phase 3 study ,we will observe the safety 、efficacy about JMKX003142 tablet in renal edema who have an inadequate…”study text, by rule · the study

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07909070Polycystic Kidney, Autosomal Dominant1Not yet recruitingMay 30, 202732
NCT07841093Edema · China3Not yet recruitingApr 30, 2028240
NCT07565441Polycystic Kidney, Autosomal Dominant1Not yet recruitingNov 15, 2026112
NCT07470177Polycystic Kidney, Autosomal Dominant1Not yet recruitingMay 14, 202624
NCT07463053Polycystic Kidney, Autosomal Dominant1Not yet recruitingMay 7, 20268
NCT06949020Edema, Cardiac · China2CompletedMar 14, 2026160
NCT06800651Polycystic Kidney, Autosomal Dominant · China2RecruitingFeb 28, 2027135
NCT06670534Edema Secondary · China2CompletedApr 27, 2026133
NCT06658964Polycystic Kidney, Autosomal Dominant1Not yet recruitingDec 10, 202448
NCT06344533Healthy Adult · China1Not yet recruitingJan 31, 202578
NCT06079541Safety and Tolerability · China1RecruitingJul 31, 2024106

How it is read

Names in the registry

  • “JMKX003142 tablets”, 8 entries
  • “JMKX003142 Injection”, 4 entries
  • “JMKX003142 will be administered orally”, 4 entries
  • “JMKX003142”, 1 entry
  • “JMKX003142 Tablets”, 1 entry

Codes read as this program: JMKX003142.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.